Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Monday, 01'st Jun 2026
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod
Geron: Time To Reconsider This Oversold Biotech
05:53am, Monday, 01'st Jun 2026
Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Tuesday, 19'th May 2026
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 18'th May 2026
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock opti
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
11:30pm, Tuesday, 12'th May 2026
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
09:31am, Tuesday, 12'th May 2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
04:21pm, Wednesday, 06'th May 2026
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
09:25am, Wednesday, 06'th May 2026
Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
07:00am, Wednesday, 06'th May 2026
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating ex
Geron Plans to Present at Upcoming Investor Conferences
08:00am, Tuesday, 05'th May 2026
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, toda
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
07:00am, Wednesday, 22'nd Apr 2026
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, to
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 20'th Apr 2026
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock
Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf
03:35am, Wednesday, 15'th Apr 2026
Geron (NASDAQ: GERN) executives used a presentation at the Needham Healthcare Conference to outline the company's early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTEL
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 14'th Apr 2026
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
08:00am, Monday, 13'th Apr 2026
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial
